At a high‑profile oncology conference this week, Chinese innovators stole the spotlight in the fiercely contested lung‑cancer market. A new Guojin Securities report shows that Chinese drug developers set a record by having the most new‑drug studies accepted for presentation: 19 full oral talks and another 45 mini‑talks. The surge reflects a rapid acceleration of home‑grown research, with several candidates moving from early‑stage trials toward late‑phase testing. While multinational giants such as Roche, Merck and AstraZeneca continue to pour billions into targeted therapies and immunotherapies, Chinese firms are narrowing the gap by focusing on novel molecular targets, next‑generation tyrosine‑kinase inhibitors, and combination regimens that promise fewer side effects. Industry analysts say the influx of Chinese data not only boosts domestic confidence but also forces global players to rethink their pipelines and partnership strategies. If the momentum holds, patients worldwide could see a broader array of affordable, effective lung‑cancer options within the next few years, marking a pivotal shift in the fight against one of the deadliest cancers.
Read moreA new industry white‑paper paints a vivid picture of China’s medical‑device sector as it shifts from relying on imports to leading global innovation. The report highlights three big trends: (1) domestic firms are rapidly replacing foreign equipment, especially in high‑growth niches like AI‑driven stroke diagnostics; (2) Chinese manufacturers are eyeing overseas markets, with a particular focus on Southeast Asia; and (3) artificial‑intelligence tools are reshaping product design, supply‑chain resilience, and clinical use. Key numbers show the market expanding from roughly 1.2 trillion RMB in 2025 to an estimated 1.8 trillion RMB by 2035. AI‑based stroke‑diagnosis devices alone could jump from 180 million RMB in 2020 to over 21 billion RMB by 2034 under a neutral growth scenario, with optimistic forecasts topping 40 billion RMB. The paper outlines three possible futures: a fully domestic‑dominant market driven by tech decoupling, a mixed landscape where premium imports coexist with affordable local products, and a leap‑frog scenario where Chinese firms lead through AI, 5G, and new materials. The analysis draws on ten recent studies from Frost & Sullivan, Tsinghua University, and major securities firms, and provides a downloadable CSV of all references. For investors and policymakers, the takeaway is clear – China’s medical‑device industry is poised for rapid, AI‑powered growth both at home and abroad.
Read moreA groundbreaking international clinical trial is set to test whether playing table tennis can slow the progression of Parkinson’s disease. The study, registered on the WHO International Clinical Trials Registry Platform, is being coordinated by Beijing Chaoyang Hospital of Capital Medical University and Longhua Hospital, which is affiliated with Shanghai University of Traditional Chinese Medicine. Launched on September 14, 2026, the trial (ChiCTR2600132425) will enroll adults diagnosed with early‑stage Parkinson’s and assign them to a structured table‑tennis exercise program or to standard care. Researchers hope that the fast‑paced, hand‑eye coordination required by the sport will improve motor function, balance, and quality of life while also offering a fun, socially engaging activity. Participants will attend supervised sessions three times a week for six months, with regular assessments of gait, tremor severity, and daily living abilities. The study’s innovative approach blends modern clinical practice with traditional Chinese medicine principles, aiming to provide a low‑cost, low‑risk adjunct therapy that could be adopted worldwide. Results are expected to be published in 2028, potentially opening a new, accessible avenue for Parkinson’s patients to stay active and maintain independence.
Read more